Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.10    0.00 (0.00%)
Bid:
7.00
Ask:
7.20
Spread: 0.20 (2.857%)
Market Cap: £3.11m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Collaboration Agreement

19 Sep 2024 07:00

RNS Number : 7696E
Feedback PLC
19 September 2024
 

Feedback plc

 

Feedback signs collaboration agreement with a provider of primary care solutions

 

Feedback plc ("Feedback" or the "Company"), has signed a collaboration agreement with a provider of primary care solutions to explore the opportunities for a novel Neighborhood Diagnostics Solution.

 

The intention is to explore creating a solution that combines the partners' technology and Bleepa to streamline NHS diagnostic and pathway referrals between primary care, Community Diagnostic Centres (CDCs) and secondary care. It is envisaged the solution will also enable some diagnostic procedures to be referred into community settings such as pharmacy or other diagnostic facilities, creating additional diagnostic capacity to support NHS waitlist recovery.

 

The parties intend to pilot the solution before pursuing broader national opportunities for contracts. Pilot conversations with customer sites are already underway. A pilot will seek to demonstrate both the continued reduction in outpatient appointment requirement through the combined platform, further reduction in patient wait times through an optimised GP referral process and also the ability to scale the solution at pace to multiple GP practices simultaneously.

 

The collaboration provides a route to rapidly scale the Bleepa solution and pathway approach, leveraging the existing footprint of the party.

 

The Company estimates that over 190m diagnostic tests per year could be redirected to a pharmacy setting. If taken to a national scale this opportunity could represent an estimated total addressable market of £382m annually with further opportunities for potential international expansion. Commercial revenue from this potential opportunity remains subject to, inter alia, successful pilots and commercial agreement between the parties.

 

 

Dr Tom Oakley, CEO, Feedback plc said: "This collaboration aligns to the Secretary of State's vision to move care out of traditional acute provider settings and into the community, closer to patients. If successful it will provide additional capacity to the NHS and help to overcome some of the difficulties being faced by CDCs, such as recruitment challenges, by enabling redirection to fully staffed facilities. It will also offer patients' choice and the convenience of attending their local high street for routine NHS investigations with, we believe, shorter wait times.

 

"Lord Darzi's paper, released on Thursday 12th September, calls directly for this solution. Given the impact that the combined product can deliver and the ability to leverage our partners existing footprint to scale the solution the Company believes that we have a huge opportunity to support the new model of the NHS under the new Labour Administration."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment, with greater connectivity across organisations.

 

Our products Bleepa® and CareLocker® work together to deliver unparalleled value to our customers. Bleepa® is our application layer and sits on top of CareLocker® as our data layer. Bleepa® is a clinician facing platform that displays clinical results from a patient's CareLocker® at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker® data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRGZGMLNRKGDZM
Date   Source Headline
19th Oct 20217:00 amRNSPilot Scheme with Sussex Integrated Care System
11th Oct 20217:00 amRNSMOU with Quest Teleradiology
29th Sep 20217:00 amRNSFeedback Joins NHS AI Procurement Framework
23rd Sep 20217:00 amRNSOfficial Launch of Bleepa Box
14th Sep 20217:00 amRNSMemorandum of Understanding with Qure.ai
9th Sep 20217:00 amRNSLaunch of CareLocker to enhance Bleepa technology
25th Aug 20217:00 amRNSChange of Adviser
3rd Aug 20217:00 amRNSDigital Health article highlights Bleepa potential
16th Jul 20217:00 amRNSBleepa agreement with CVS Equine Division
5th Jul 202110:17 amRNSHolding(s) in Company
30th Jun 20213:30 pmRNSBoard Update
29th Jun 20217:00 amRNSUK Medical Device Certification for Bleepa
10th Jun 20217:00 amRNSBleepa available on Apple App Store & Google Play
8th Jun 20217:00 amRNSYear End Trading Update
6th May 20217:00 amRNSExecutive Appointment
24th Mar 20217:00 amRNSRoyal Berkshire NHS Foundation Trust Contract
23rd Feb 20217:00 amRNSHalf-year Report
19th Jan 20217:00 amRNSBleepa builds on robust data management security
4th Dec 20207:00 amRNSBleepa to join DIT’s first virtual event to India
10th Nov 20209:06 amRNSSelected for Digitalhealth.London 2020 Programme
6th Nov 20203:03 pmRNSResult of Annual General Meeting - Amendment
6th Nov 20201:50 pmRNSHolding(s) in Company
5th Nov 20201:23 pmRNSResult of AGM
5th Nov 20207:01 amRNSBleepa selected for WISH 2020 Innovation Awards
5th Nov 20207:00 amRNSAGM Statement
28th Oct 20203:10 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSBleepa adds 3D Imaging with Axial3D Partnership
13th Oct 20207:00 amRNSFinal Results
26th Aug 20201:34 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSDirector/PDMR Shareholding
5th Aug 20204:36 pmRNSPrice Monitoring Extension
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 20203:48 pmRNSBleepa appointed to major NHSx framework
29th Jul 20202:06 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSAppointment of Non-Executive Director
10th Jul 20207:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 202011:01 amRNSHolding(s) in Company
6th Jul 202010:36 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 202012:46 pmRNSResult of Open Offer and General Meeting
25th Jun 202011:59 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSPlacing, Open Offer and Notice of GM
1st Jun 20207:00 amRNSBleepa® achieves CE Mark
21st May 20207:00 amRNSPapworth NHS Hosp - contract renewal with Bleepa
29th Apr 20202:05 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.